Risque hémorragique de la drotrécogine alfa (activée) dans le sepsis sévèrePERROTIN, D.Annales françaises d'anesthésie et de réanimation. 2003, Vol 22, pp 16-19, issn 0750-7658, 4 p., HS1Conference Paper

The use of drotrecogin alfa in severe falciparum malariaROBAK, O; BOJIC, A; LOCKER, G. J et al.Anaesthesia and intensive care. 2010, Vol 38, Num 4, pp 751-754, issn 0310-057X, 4 p.Article

How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? A Bayesian designKALIL, Andre C; JUNFENG SUN.Intensive care medicine (Print). 2008, Vol 34, Num 10, pp 1804-1811, issn 0342-4642, 8 p.Article

Approche clinique de l'identification des patients en sepsis sévère avec plusieurs défaillances d'organe pour l'administration de drotrécogine alfa (activée) : de l'étude Prowess à la pratique cliniqueDHAINAUT, J.-F; PAYEN, D.-M; BERNARDIN, G et al.Annales françaises d'anesthésie et de réanimation. 2003, Vol 22, pp 53-64, issn 0750-7658, 12 p., HS1Conference Paper

Question de l'agence européenne du médicament (EMEA) : interaction drotrécogine alfa (activée) et héparine à dose prophylactiqueMESHAKA, P.Annales françaises d'anesthésie et de réanimation. 2003, Vol 22, pp 23-27, issn 0750-7658, 5 p., HS1Conference Paper

The use of drotrecogin alfa (activated) in a patient with recent orthotopic liver transplantBROWNE, E; CRESSEY, D. M; AGARWAL, K et al.Anaesthesia. 2007, Vol 62, Num 3, pp 282-285, issn 0003-2409, 4 p.Article

Traitements nouveaux du choc septique : Un médicament et des pistes pour réduire la mortalité = Treatments of septic shocksCHARPENTIER, Julien; CARLOU, Alain.La Revue du praticien (Paris). 2004, Vol 54, Num 5, pp 475-476, issn 0035-2640, 2 p.Article

Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregressionKALIL, Andre C; LAROSA, Steven P.Lancet. Infectious diseases (print). 2012, Vol 12, Num 9, pp 678-686, issn 1473-3099, 9 p.Article

Drotrécogine alfa : Surmortalité chez les malades les moins graves = Drotrecogin alfa: overmortality in less severe patientLa Revue Prescrire. 2005, Vol 25, Num 260, issn 0247-7750, p. 275Article

Stopping Trials Early for Benefit—Not So Fast!FAUST, Andrew C; CHUNG, Tammy; FELDMAN, Mark et al.The Annals of pharmacotherapy. 2012, Vol 46, Num 11, pp 1564-1567, issn 1060-0280, 4 p.Article

Adjunctive therapies for severe sepsisWITTEBOLE, X; COLLIENNE, C; CASTANARES-ZAPATERO, D et al.International journal of antimicrobial agents (Print). 2008, Vol 32, issn 0924-8579, S34-S38, SUP1Conference Paper

Use of Drotrecogin alfa (activated) in Italian intensive care units : the results of a nationwide surveyBERTOLINI, Guido; ROSSI, Carlotta; ANGHILERI, Abramo et al.Intensive care medicine (Print). 2007, Vol 33, Num 3, pp 426-434, issn 0342-4642, 9 p.Article

Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsisBARIE, Philip S; WILLIAMS, Mark D; MCCOLLAM, Jill Shwed et al.The American journal of surgery. 2004, Vol 188, Num 3, pp 212-220, issn 0002-9610, 9 p.Article

Activated protein C for the treatment of severe sepsisHOUSTON, G; CUTHBERTSON, B. H.Clinical microbiology and infection. 2009, Vol 15, Num 4, pp 319-324, issn 1198-743X, 6 p.Article

Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis : a Canadian multicenter observational studyKANJI, Salmaan; PERREAULT, Marc M; CHANT, Clarence et al.Intensive care medicine (Print). 2007, Vol 33, Num 3, pp 517-523, issn 0342-4642, 7 p.Article

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of deathABRAHAM, Edward; LATERRE, Pierre-Francois; ROSSAINT, Rolf et al.The New England journal of medicine. 2005, Vol 353, Num 13, pp 1332-1341, issn 0028-4793, 10 p.Article

Coagulopathy of sepsisDEMPFLE, Carl-Erik.Thrombosis and haemostasis. 2004, Vol 91, Num 2, pp 213-224, issn 0340-6245, 12 p.Article

Protein C/activated protein C pathway: Overview of clinical trial results in severe sepsisDHAINAUT, Jean-Francois; YAN, S. Betty; CLAESSENS, Yann-Erick et al.Critical care medicine. 2004, Vol 32, Num 5, pp S194-S201, issn 0090-3493, SUPConference Paper

Recombinant human activated protein CHUGHES, Martin.International journal of antimicrobial agents. 2006, Vol 28, Num 2, pp 90-94, issn 0924-8579, 5 p.Article

Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signalingWEI ZENG; MATTER, William F; YAN, S. Betty et al.Critical care medicine. 2004, Vol 32, Num 5, pp S302-S308, issn 0090-3493, SUPConference Paper

Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautionsGENTRY, Chris A; BUSSE GROSS, Kristin; SUD, Bhanu et al.Critical care medicine. 2009, Vol 37, Num 1, pp 19-25, issn 0090-3493, 7 p.Article

Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shockDHAINAUT, Jean-Francois; ANTONELLI, Massimo; MIGNINI, Mariano A et al.Intensive care medicine (Print). 2009, Vol 35, Num 7, pp 1187-1195, issn 0342-4642, 9 p.Article

A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis : Comparison with a controlled clinical trialWHEELER, Arthur; STEINGRUB, Jay; SCHMIDT, Gregory A et al.Critical care medicine. 2008, Vol 36, Num 1, pp 14-23, issn 0090-3493, 10 p.Article

Activated protein C (Xigris®) treatment in sepsis : a drug in troubleGARDLUND, B.Acta anaesthesiologica scandinavica. 2006, Vol 50, Num 8, pp 907-910, issn 0001-5172, 4 p.Article

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE : Further evidence for survival and safety and implications for early treatmentVINCENT, Jean-Louis; BERNARD, Gordon R; WONG, Kar et al.Critical care medicine. 2005, Vol 33, Num 10, pp 2266-2277, issn 0090-3493, 12 p.Article